What is Co Diagnostics?
Headquartered in Salt Lake City, Utah, Co-Dx specializes in the development, manufacturing, and distribution of reagents and diagnostic platforms designed for the precise detection and analysis of nucleic acid molecules. The company's core innovation, the Co-Dx PCR platform, is engineered to bring high-fidelity molecular testing into point-of-care and at-home environments, effectively decentralizing diagnostic access.
Beyond its flagship PCR technology, the company maintains a diverse portfolio that includes diagnostic tests for a wide array of infectious diseases, such as COVID-19, influenza, and various vector-borne illnesses. Furthermore, Co-Dx has diversified its operational scope to include liquid biopsy for cancer screening, agricultural genomic analysis, and mosquito-borne disease surveillance. This multi-faceted approach allows the company to address critical gaps in global health security and precision medicine, establishing it as a versatile entity in the competitive molecular diagnostics landscape.
How much funding has Co Diagnostics raised?
Co Diagnostics has raised a total of $13.1M across 4 funding rounds:
Debt
$750K
Stock Offering
$7.1M
Grant
$2.3M
Stock/Share Issuance
$3M
Debt (2016): $750K, investors not publicly disclosed
Stock Issuance/Offering (2017): $7.1M, investors not publicly disclosed
Grant (2023): $2.3M supported by Bill & Melinda Gates Foundation
Stock/Share Issuance (2026): $3M, investors not publicly disclosed
Key Investors in Co Diagnostics
Bill & Melinda Gates Foundation
A global philanthropic organization focused on enhancing healthcare outcomes and reducing extreme poverty through strategic investments in medical research and diagnostic accessibility.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Co Diagnostics?
With the recent influx of capital, Co-Dx is poised to accelerate its research and development initiatives, specifically focusing on the miniaturization of its diagnostic hardware and the expansion of its multiplexed testing menu. The strategic roadmap emphasizes the integration of its portable PCR devices into broader healthcare networks, aiming to reduce the time-to-result for critical patient diagnostics.
Market analysts anticipate that the company will prioritize scaling its manufacturing capacity to meet the rising demand for rapid, reliable molecular testing. By continuing to refine its proprietary technology and exploring new applications in liquid biopsy and agricultural genomics, Co-Dx is strategically aligning itself to capture significant market share in the evolving diagnostics industry. The focus remains on operational efficiency and the commercialization of its next-generation diagnostic tools to ensure long-term sustainability and impact.
